Liquid-filled gelatin capsules

Pharmacopeial Forum

Volumn 35, Issue 4, 2009, Pages 1029-1041

  Marques, Margareth R C ^a,b   Cole, Ewart ^c   Kruep, Dale ^d   Gray, Vivian ^e   Murachanian, Dennis ^c   Brown, William E ^a   Giancaspro, Gabriel I ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNITED STATES PHARMACOPEIA   (United States)

^c PFIZER INC   (United States)

^d Banner Pharmacaps Inc   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLODEXTRIN; DECANOIC ACID; EXCIPIENT; GELATIN; LABRASOL; MACROGOL 4000; METHYLBENZETHONIUM CHLORIDE; MIGLYOL; OCTANOIN; OLEIC ACID; PHOSPHATIDYLCHOLINE; POLYSORBATE; POLYSORBATE 80; PROPYLENE GLYCOL; TETRADECYL SULFATE SODIUM;

DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG NOMENCLATURE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; PHARMACEUTICS; REVIEW;

EID: 68849095520     PISSN: 03634655     EISSN: 15421945     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Ghebre-Sellassie I. Multiparticulate Oral Drug Delivery. New York, NY: Marcel Dekker; 1994.
2. Walker SE, Bedford K, Eaves T. British patent 1.572.226. 30 July 1980.
3. McTaggart C, Wood R, Bedford K, Walker SE. The evaluation of an automatic system for filling liquids into hard gelatin capsules. J Pharm Pharmacol. 1984;36:119-121. (Pubitemid 14188598)
4. Cuiné A, Mathis C, Stamm A, François D. Das Einbringen viskoser Lösungen von Aktivstoffen in Hartgelatinekapseln. Pharm. Ind. 1987;40(6):654-657.
5. Cole ET. Liquid-filled hard gelatin capsules. Pharm Technol Int. 1989;1(5):29-33.
6. Wittwer F. New developments in hermetic sealing of hard gelatin capsules. Pharm Manuf. 1985;2:24-27.
7. Bowtle WJ. Liquid filling of hard gelatin capsules: a new technology for alternative formulations. Pharm Technol Europe. 1998;10:84-90.
8. Cadé D, Cole ET, Mayer JP, Wittwer F. Liquid-filled and sealed hard gelatin capsules. Acta Pharm Technol. 1987;33(2):97-100.
9. Cole ET. Liquid-filled and sealed hard gelatin capsule technologies. In: Rathbone MJ, Hadgraft J, Roberts MS, eds. Modified-release Drug Delivery Technology. New York, NY: Marcel Dekker; 2003:126,177-190.
10. USP. USP 31-NF 26, Pharmaceutical Dosage Forms (1151). Rockville, MD: US Pharmacopeial Convention; 2008:615-626.
11. Jolley JE. The microstructure of gelatin binders. Photogr Sci Eng. 1970;14(3):167-177.
12. USP. USP 31-NF 26. Rockville, MD: US Pharmacopeial Convention; 2008:1139.
13. Bond CM, Lees KA, Packington JL. Cephalexin: a new oral broad-spectrum antibiotic. Pharm J. 1970;205:210-214.
14. Kontny MJ, Mulski CA. Gelatin capsule brittleness as a function of relative humidity at room temperature. Int J Pharm. 1989;54:79-85.
15. Cadé D, Madit N. Liquid filling in hard gelatin capsules- preliminary steps. B. T. Gattefossé. 1996;89:15-19.
16. Carstensen JT, Rhodes CR. Drug Dev Ind Pharm. 1993;83:915-921.
17. Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci. 1994;83:915-921.
18. Schwier JR, Cooke GG, Hartauer KJ, Yu L. A reactive aldehyde capable of insolubilizing gelatin capsules. Pharm Technol. 1993;17:78-80.
19. Murthy KS, Enders NA, Fawzi MB. Dissolution stability of hard-shell products. Part I. The effect of exaggerated storage conditions. Pharm Technol. 1989;13:72-84.
20. Murthy KS, Reisch RG, Fawzi MB. Dissolution stability of hard-shell products. Part II. The effect of dissolution test conditions on in vitro drug release. Pharm. Technol. 1989;13:53-58.
21. Brown J, Madit. N, Cole ET, Wilding IR, Cadé D. The effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharm Res. 1998;15:1026-1030. (Pubitemid 28356918)
22. Meyer MC, Straughn AB, Mhatre RM, et al. The effect of gelatin cross-linking on the bioequivalence of hard and soft gelatin acetaminophen capsules. Pharm Res. 2000;17:962-966.
23. USP. USP 31-NF 26, Dissolution (711). Rockville, MD: US Pharmacopeial Convention; 2008:267.
24. Ghirardi P, Catenazzo G, Mantero O, Merotti GC, Marzo A. Bioavailability of digoxin in a new soluble pharmaceutical formulation in capsules. J Pharm Sci. 1977;66(2):267-269. (Pubitemid 8040035)
25. Lahr W. Flüssig befüllte Hartgelatinekapseln. Pharm Ztg. 1986;131(15):871-874.
26. Herrmann R. Bioverfügbarkeit zweier neuer Nifedipin-Formulierungen. Pharm Ztg. 1986;131(15):869-870.
27. Lipinski CA. Strategies for optimizing oral drug delivery. Kobe, April 19-21, 1999.
28. Robinson JR. Introduction: semi-solid formulations for oral drug delivery. B. T. Gattefossé. 1996;189:11.
29. Kovarik JM, Mueller EA, Van-Bree JB, Tetzloff W, Kutz K. Re- duced inter- and intraindividual variability in cyclosporin pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83:444-446. (Pubitemid 24224228)
30. Meinzer A, Richter F, Vonderscher JF. Oil-free pharmaceutical compositions containing cyclosporin A. Patent WO 93/ 20833. 1993.
31. Walker SE, Ganley JA, Bedford K, Eaves T. The filling of molten and thixotropic formulations into hard gelatin capsules. J Pharm Pharmacol. 980;32:389-393.
32. Howard JR, Gould PL. Drug release from thermosetting fatty vehicles filled into hard gelatin capsules. Drug Dev Ind Pharm. 1987;13(6):1031-1045. (Pubitemid 17100412)
33. Bernasconi AC, Doelker E, Buri P. Diffusion and erosion controlled drug release from lipid matrix formulations incorporated into hard gelatin capsules. Proc Int Symp Control Rel Bioact Matr. 1985;12:272-273.
34. Dennis AB, Kellaway IW, Davidson R. Investigation of in-vitro aging on in vivo release from a prolonged release liquid-filled hard gelatin capsule formulation. Proc Int Symp Control Rel Bioact Matr. 1988;15:390-391.
35. Seta Y, Higuchi F, Kawahara Y, Nishimura K, Okada R. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int J Pharm. 1988;41:245-254. (Pubitemid 18034878)
36. Seta Y, Higushi F, Otsuka T, et al. Preparation and pharmacological evaluation of captopril sustained-release dosage forms using oily semisolid matrix. Int J Pharm. 1988;41:255-262. (Pubitemid 18034879)
37. Seta Y, Otsuka T, Tokiwa H, et al. Design of captopril sustained-release preparation with oily semisolid matrix intended for use in human subjects. Int J Pharm. 1988;41:263-269. (Pubitemid 18034880)
38. Cole ET. Liquid-filled and sealed hard gelatin capsules. B. T. Gattefossé. 1999;92:67-77.
39. Duerr M, Fridolin HU, Gneuss KD. Entwicklung von Rezepturen und Verfahren zur Abfüllung von flüssigen Massen in Hartgelatinekapseln unter Produktionsbedingungen. Acta Pharm Technol. 1983;29(3):245-251.
40. Lucas RA, Bowtle WJ, Ryden R. Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules. J Clin Pharm Ther. 1987;12:27-31. (Pubitemid 17066902)
41. Bowtle WJ, Barker NJ, Wodhams J. A new approach to vancomycin formulation using filling technology for semisolid matrix capsules. Pharm Technol. 1988;12(6):86-97.
42. Doelker C, Doelker E, Buri P, Waginaire L. The incorporation and in vitro release profile of liquid, deliquescent or unstable drugs with fusible excipients in hard gelatin capsules. Drug Dev Ind Pharm. 1986;12(10):1553-1565. (Pubitemid 16050191)
43. Chatham SM. The use of bases in semi-solid matrix formulations. S. T. P. Pharma. 1987;3(7):575-582.
44. Galal S, El-Massik M, Abdallah O, Daabis N. Formulation of fast release glibenclamide liquid and semi-solid matrix filled capsules. Acta Pharm. 2003;53:57-64. (Pubitemid 36514236)
45. Ofner CM III, Zhang Y, Jobeck VC, Bowman BJ. Crosslinking studies in gelatin capsules treated with formaldehyde and in capsules exposed to elevated temperature and humidity. J Pharm Sci. 2001;90(1):79-88. (Pubitemid 32050479)
46. Lozano R, et al. Gelatin cross-linking in capsules and its effect on dissolution. Am Pharm Rev. 2001;4(4):8-16.
47. Singh S, et al. Alteration in dissolution characteristics of gelatin-containing formulations. A review of the problem, test methods, and solutions. Pharm Technol. 2002;26(4):36-58.
48. Kenley RA, Chaudhry S, Visor, GC. Multidimensional column-switching liquid chromatographic method for dissolution testing of enprostil soft elastic gelatin capsules. J Pharm Sci. 1986;75(10):999-1002. (Pubitemid 17182379)
49. Pillay V, Fassihi R. A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug. Pharm Res. 1999;16:333-337. (Pubitemid 29135142)
50. Wasan KM. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev Ind Pharm. 2001;27:267-276.
51. Siewert M, et. al. FIP/AAPS guidelines to dissolution in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:7.
52. Porter CJH, Charman, WN. In vitro assessment of oral lipid based formulations. Adv Drug Del Dev. 2001;50:S127-S147.
53. USP. USP 31-NF 26, Disintegration and Dissolution of Dietary Supplements (2040). Rockville, MD: US Pharmacopeial Convention; 2008:732-736.
54. Humberstone, AJ, Charman, WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Del Res. 1997;25:103-128.
55. Pouton, CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Reviews. 1997;25:47-58. (Pubitemid 27107790)
56. Han JH, Gallery J. A risk based approach to in vitro performance testing: a case study on the use of dissolution versus disintegration for liquid filled soft gelatin capsules. Am Pharm Rev. 2006;9(6):152-157.
57. FDA. Guidance for Industry-Dissolution Testing of Immediate Release Solid Oral Dosage Forms. 1997. Available at www.fda.gov/cder/guidance/1713bp1.pdf. Accessed 2 March 2009.
58. Noory C, Tran N, Ouderkirk L, Shah V. Steps for development of a dissolution test for sparingly water-soluble drug products. Dissol Technol. 2000;7(1):16-18. (Pubitemid 36024259)
59. Rohrs BR. Dissolution method development for poorly soluble compounds. Dissol Technol. 2001;8(3):6-12.
60. Marchais, H, et al. Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release. Eur J Pharm Sci. 2003;19:129-132 (Pubitemid 36668039)
61. Savelli G, Spreti N, Di Profio P. Enzyme activity and stability control by amphiphilic self-organizing systems in aqueous solutions. Curr Opinion Coll Int Sci. 2000;5:111-117. (Pubitemid 30705747)
62. Maes P, Brusselmans J, Sereno A, Pitti C, Sonck M, Coffiner M. In vitro and in vivo behavior of some liquid or semi-solid filled hard gelatin capsules. B. T. Gattefosse, 1996;89:63-69.
63. USP. USP 31-NF 26, Drug Release (724). Rockville, MD: US Pharmacopeial Convention; 2008:275-278.
64. Bottom CB, Clark M, Carstensen, JT Dissolution testing of soft shell capsules-acetaminophen and nifedipine. J Pharm Sci. 1997;86(9):1057-1061.
65. El-Arini SK, Shiu GK, Skelly P. Theophylline-controlled re-lease preparations and fatty food. An in vitro study using rotating dialysis cell method. Pharm Res. 1990;7(11):1134-1140.
66. Takahashi M, et al. Studies on dissolution tests for soft ge-latin capsules. IV. Dissolution test of nifedipine soft gelatin capsule containing water soluble vehicles by the rotating dialysis cell method. Chem Pharm Bull. 1994;42(2):333-336.
67. Takahashi, M, et al. Studies on dissolution tests of soft ge-latin capsules. V. Rotating dialysis cell method. Chem Pharm Bull. 1994;42(8):1672-1675.
68. Takahashi M, et al. Studies on dissolution tests for soft gelatin capsules by the rotating dialysis cell (RDC) method. VI. Preparation and evaluation of ibuprofen soft gelatin capsule. Chem Pharm Bull. 1995;43(8):1398-1401.
69. Burns SJ, et al. Development and validation of an in vitro dissolution method for a floating dosage form with biphasic release characteristics. Int J Pharm. 1995;121:37-44.
70. Burns SJ, et al. Formulation strategies designed to maintain the biphasic release characteristics of liquid-filled capsules. Int J Pharm. 1996;141:9-16.
71. Burns SJ, et al. A study of enteric-coated liquid-filled hard gelatin capsules with biphasic release characteristics. Int J Pharm. 1994;110:291-296.
72. Moller H. Dissolution testing of different dosage forms using the flow-through method. Pharm Ind. 1983;45(6):617-622.
73. Gjellan K, Graffner C. Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow-through methods. I - Paracetamol in suppositories and soft gelatin capsules of both hydrophilic and lipophilic types. Acta Pharm Nord. 1989;1(6):343-354.
74. Hu J, Kyad A, Ku V, Zhou P, Cauchon N. A comparison of dissolution testing on lipid soft gelatin capsules using USP Apparatus 2 and Apparatus 4. Dissol Tech. 2005;12(2):6-9.
75. Aikman M, et al. Collaborative development of two-tier dis-solution testing for gelatin capsules and gelatin-coated tablets using enzyme-containing media. Pharm Forum. 1998;24(5):7045-7050.
76. ICH. Guidance on specifications: test procedure and acceptance criteria for new drug substances and new drug products: chemical substances, Q6A. Fed. Reg. 2000,65(251):83041-83063.
77. Gallery J, Han JH, Abraham C. Pepsin and pancreatin performance in the dissolution of crosslinked gelatin capsules from pH 1 to 8. Pharm Forum. 2004;30(3):1084-1089.